CRVS Share Price | Corvus Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Corvus Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Corvus Pharmaceuticals, Inc. has a market capitalization of 303.83 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Corvus Pharmaceuticals reported net sales of 0.00 million and a net profit of -41.40 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 32.57 million and total assets of 68.91 million.

Q: What does Corvus Pharmaceuticals, Inc. do?

Overview:Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapies within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:- Most recent Net Profit: 15 Million (Quarterly Results - Mar 2025)- Market cap: USD 303.83 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.89- Return on Equity: -67.21%- Price to Book: 6.16Contact Details:- Address: 863 Mitten Rd Ste 102, BURLINGAME CA: 94010-1311- Tel: ['1 650 9004520', '1 650 9004522']- Fax: 1 302 6555049- Website: http://www.corvuspharma.com/

Q: Is Corvus Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Corvus Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly MACD and KST are mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of performance, Corvus Pharmaceuticals has outperformed the S&P 500 over the past month with a return of 15.04% compared to the S&P's 2.33%, and it has a substantial 3-year return of 563.49% versus the S&P's 70.41%. Overall, the current technical stance is bullish with strong momentum indicators, although some longer-term metrics show mixed signals.

Results Declared: Corvus Pharmaceuticals, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.93 M

Shareholding (Dec 2025)

FII

2.75%

Held by 39 FIIs

DII

61.54%

Held by 17 DIIs

Promoter

23.83%

How big is Corvus Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Corvus Pharmaceuticals, Inc. has a market capitalization of 303.83 million, with net sales of 0.00 million and a net profit of -41.40 million over the last four quarters. The company reported shareholder's funds of 32.57 million and total assets of 68.91 million as of Dec 24.

View full answer

What does Corvus Pharmaceuticals, Inc. do?

22-Jun-2025

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. As of March 2025, it has a market cap of $303.83 million and reported a net profit of $15 million.

View full answer

Who are in the management team of Corvus Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Corvus Pharmaceuticals, Inc. includes Mr. Richard Miller (Chairman, President, and CEO) and Dr. Edith Mitchell (Director), along with Independent Directors Mr. Ian Clark, Mr. Elisha Gould, Dr. Linda Grais, and Mr. Steve Krognes.

View full answer

Is Corvus Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Corvus Pharmaceuticals shows a bullish trend with strong momentum indicators, having outperformed the S&P 500 recently, although some longer-term metrics indicate caution.

View full answer

Compare Corvus Pharmaceuticals, Inc. with Similar Stocks

DURECT Corp.G1 Therapeutics, Inc.Immix Biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,320 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-55.55%

Price to Book

18.40

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

74.48%

6 Months

117.81%

1 Year

184.22%

2 Years

601.58%

3 Years

1713.36%

4 Years

657.39%

5 Years

319.18%

Corvus Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

2.70%

EBIT to Interest (avg)

-46.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.89

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

72.79%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.40

EV to EBIT

-32.30

EV to EBITDA

-32.38

EV to Capital Employed

194.34

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-601.72%

ROE (Latest)

-55.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 23 Schemes (11.87%)

Foreign Institutions

Held by 39 Foreign Institutions (2.75%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -1.65% vs -80.60% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.20",
          "val2": "-8.10",
          "chgp": "-50.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.30",
          "val2": "-12.10",
          "chgp": "-1.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 75.44% vs -130.74% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.90",
          "val2": "-27.50",
          "chgp": "-56.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "27.10",
          "val2": "-33.40",
          "chgp": "181.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.30",
          "val2": "-62.30",
          "chgp": "75.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-12.20

-8.10

-50.62%

Interest

0.00

Exceptional Items

0.00

-2.30

100.00%

Consolidate Net Profit

-12.30

-12.10

-1.65%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -1.65% vs -80.60% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-42.90

-27.50

-56.00%

Interest

0.00

Exceptional Items

27.10

-33.40

181.14%

Consolidate Net Profit

-15.30

-62.30

75.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 75.44% vs -130.74% in Dec 2024

All Annual Results

Company CV

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Company Coordinates

Company Details

863 Mitten Rd Ste 102 , BURLINGAME CA : 94010-1311

Tel: 1 650 90045201 650 9004522

http://www.corvuspharma.com/

Registrar Details